Abivax Raises $800 Million Through ADS Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 41 minutes ago
0mins
Source: stocktwits
- Increased Offering Size: Abivax announced a public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, raising the total offering size from $600 million to $800 million, reflecting strong market confidence in its drug candidate.
- Clear Use of Proceeds: The net proceeds from the offering will be allocated towards the commercialization of the lead drug candidate obefazimod in the U.S. and clinical research, effectively supporting the company's operational funding needs until Q2 2029.
- Extended Cash Runway: As of March 31, Abivax reported approximately €491.6 million in cash and cash equivalents, and with the new funding, the company expects to extend its cash runway into Q2 2029, enhancing its survival prospects in the market.
- Optimistic Market Sentiment: Despite the offering leading to an 8% dilution of share capital, retail sentiment on Stocktwits remains bullish, indicating strong confidence in Abivax's future growth potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABVX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABVX
Wall Street analysts forecast ABVX stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 133.260
Low
131.00
Averages
150.71
High
175.00
Current: 133.260
Low
131.00
Averages
150.71
High
175.00
About ABVX
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Temporarily Halts Trading on Euronext Paris
- Trading Halt: Abivax SA has requested a temporary halt in trading on Euronext Paris starting at 9:00 a.m. CEST on July 1, 2026, with trading expected to resume at approximately 3:30 p.m. the same day, aligning with its previously announced ADS offering.
- ADS Offering: The company announced a $600 million offering of American Depositary Shares (ADS), each representing one ordinary share with a nominal value of €0.01, aimed at funding the development of its lead drug candidate, Obefazimod.
- Use of Proceeds: The gross proceeds from this offering will primarily support clinical research and development expenses for Obefazimod, particularly in treating moderately to severely active ulcerative colitis and Crohn's disease, highlighting the company's strategic focus in the biopharmaceutical sector.
- Market Reaction: Prior to the trading halt, Abivax's stock closed at $136.40 on Nasdaq, reflecting a 2.36% increase, indicating positive market sentiment towards the ADS offering and the company's growth prospects.
See More
Abivax Raises $800 Million Through ADS Offering
- Increased Offering Size: Abivax announced a public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, raising the total offering size from $600 million to $800 million, reflecting strong market confidence in its drug candidate.
- Clear Use of Proceeds: The net proceeds from the offering will be allocated towards the commercialization of the lead drug candidate obefazimod in the U.S. and clinical research, effectively supporting the company's operational funding needs until Q2 2029.
- Extended Cash Runway: As of March 31, Abivax reported approximately €491.6 million in cash and cash equivalents, and with the new funding, the company expects to extend its cash runway into Q2 2029, enhancing its survival prospects in the market.
- Optimistic Market Sentiment: Despite the offering leading to an 8% dilution of share capital, retail sentiment on Stocktwits remains bullish, indicating strong confidence in Abivax's future growth potential.
See More
ABIVAX Prices Public Offering of 6.4 Million ADSs
- Offering Size: ABIVAX announced the pricing of 6.4 million American Depositary Shares (ADS) at $125 each, expected to raise approximately $800 million for the commercialization of its lead drug candidate, obefazimod, and clinical research expenses.
- Underwriter Option: The underwriters have an option to purchase up to an additional 960,000 ADSs, enhancing the flexibility of the financing and ensuring the company has greater security for future funding needs.
- Positive Market Reaction: In pre-market trading, ABIVAX's stock rose 2.80% to $136.99 on Nasdaq, reflecting investor confidence in the company's future and recognition of its drug development potential.
- Clear Use of Funds: The proceeds will primarily fund clinical research and development related to ulcerative colitis and Crohn's disease, indicating the company's strategic focus in the gastrointestinal disease sector and aiming to accelerate its product commercialization efforts.
See More
Abivax Prices Oversubscribed $800M Public Offering
- Upsized Offering: Abivax has increased its public offering from the initially planned $600 million to $800 million, pricing each American Depositary Share (ADS) at $125, reflecting a 2.39% premium over the three-day VWAP, indicating strong market demand and expected gross proceeds of approximately $800 million to support future commercialization and clinical development.
- Clear Use of Proceeds: The funds raised will be allocated to support the commercialization of its lead drug candidate, obefazimod, and clinical research related to ulcerative colitis and Crohn's disease, extending the company's cash runway into Q2 2029, ensuring continued operations in the competitive biopharmaceutical market.
- Underwriters' Option: The company has granted underwriters an option to purchase up to 960,000 additional ADSs before July 6, 2026, which, if fully exercised, could raise total proceeds to approximately $920 million, further strengthening the company's financial position for R&D and market expansion.
- Dilution Impact: The issuance of 6.4 million ADSs will result in an approximate 8% dilution of the company's share capital, increasing to 9.2% if the underwriters' option is fully exercised, which may affect existing shareholders' stakes and warrants investor attention.
See More
Abivax Upsizes Public Offering to $800M, Plans for Obefazimod Commercialization
- Offering Size Increased: Abivax SA has upsized its public offering from the initially planned $600 million to $800 million by pricing 6.4 million ADSs at $125 each, reflecting strong market demand for its products.
- Potential Financing Boost: The offering includes a 15% option for underwriters to purchase up to 960,000 additional ADSs, which could raise total gross proceeds to approximately $920 million if fully exercised, further strengthening the company's financial position.
- Clear Use of Proceeds: Abivax intends to use the proceeds to support the commercialization of obefazimod, fund clinical development, and for general corporate purposes, demonstrating the company's strong confidence in future product marketability.
- Expected Closing Date: The public offering is expected to close on July 6, 2026, marking an active capital market strategy that lays a solid foundation for the company's future growth.
See More
Latest Wall Street Rating Updates
- Abbott Labs Upgrade: Baird initiates coverage on Abbott Labs (ABT) with an outperform rating, projecting steady revenue and earnings growth of 6-8% over the next few years, bolstered by its leading position in the rapidly growing MedDevice market, enhancing the company's competitive edge.
- Murphy USA Upgrade: Jefferies upgrades Murphy USA (MUSA) from hold to buy, citing improving fuel margins that are expected to drive EBITDA outlook significantly higher by 20-25%, which will materially enhance the company's financial performance in the coming years.
- Abivax Upgrade: Jefferies raises Abivax (ABVX) to buy, noting strong data for its ulcerative colitis drug that alleviates key market concerns, which is likely to drive a rebound in the stock price.
- Talos Energy Upgrade: Roth upgrades Talos Energy (TALO) from neutral to buy, raising the price target by 6% to $17, based on its robust balance sheet and low production decline rates, indicating strong future growth potential.
See More
Abivax Temporarily Halts Trading on Euronext Paris
- Trading Halt: Abivax SA has requested a temporary halt in trading on Euronext Paris starting at 9:00 a.m. CEST on July 1, 2026, with trading expected to resume at approximately 3:30 p.m. the same day, aligning with its previously announced ADS offering.
- ADS Offering: The company announced a $600 million offering of American Depositary Shares (ADS), each representing one ordinary share with a nominal value of €0.01, aimed at funding the development of its lead drug candidate, Obefazimod.
- Use of Proceeds: The gross proceeds from this offering will primarily support clinical research and development expenses for Obefazimod, particularly in treating moderately to severely active ulcerative colitis and Crohn's disease, highlighting the company's strategic focus in the biopharmaceutical sector.
- Market Reaction: Prior to the trading halt, Abivax's stock closed at $136.40 on Nasdaq, reflecting a 2.36% increase, indicating positive market sentiment towards the ADS offering and the company's growth prospects.
See More
Abivax Raises $800 Million Through ADS Offering
- Increased Offering Size: Abivax announced a public offering of 6.4 million American Depositary Shares (ADSs) at $125 each, raising the total offering size from $600 million to $800 million, reflecting strong market confidence in its drug candidate.
- Clear Use of Proceeds: The net proceeds from the offering will be allocated towards the commercialization of the lead drug candidate obefazimod in the U.S. and clinical research, effectively supporting the company's operational funding needs until Q2 2029.
- Extended Cash Runway: As of March 31, Abivax reported approximately €491.6 million in cash and cash equivalents, and with the new funding, the company expects to extend its cash runway into Q2 2029, enhancing its survival prospects in the market.
- Optimistic Market Sentiment: Despite the offering leading to an 8% dilution of share capital, retail sentiment on Stocktwits remains bullish, indicating strong confidence in Abivax's future growth potential.
See More
ABIVAX Prices Public Offering of 6.4 Million ADSs
- Offering Size: ABIVAX announced the pricing of 6.4 million American Depositary Shares (ADS) at $125 each, expected to raise approximately $800 million for the commercialization of its lead drug candidate, obefazimod, and clinical research expenses.
- Underwriter Option: The underwriters have an option to purchase up to an additional 960,000 ADSs, enhancing the flexibility of the financing and ensuring the company has greater security for future funding needs.
- Positive Market Reaction: In pre-market trading, ABIVAX's stock rose 2.80% to $136.99 on Nasdaq, reflecting investor confidence in the company's future and recognition of its drug development potential.
- Clear Use of Funds: The proceeds will primarily fund clinical research and development related to ulcerative colitis and Crohn's disease, indicating the company's strategic focus in the gastrointestinal disease sector and aiming to accelerate its product commercialization efforts.
See More
Abivax Prices Oversubscribed $800M Public Offering
- Upsized Offering: Abivax has increased its public offering from the initially planned $600 million to $800 million, pricing each American Depositary Share (ADS) at $125, reflecting a 2.39% premium over the three-day VWAP, indicating strong market demand and expected gross proceeds of approximately $800 million to support future commercialization and clinical development.
- Clear Use of Proceeds: The funds raised will be allocated to support the commercialization of its lead drug candidate, obefazimod, and clinical research related to ulcerative colitis and Crohn's disease, extending the company's cash runway into Q2 2029, ensuring continued operations in the competitive biopharmaceutical market.
- Underwriters' Option: The company has granted underwriters an option to purchase up to 960,000 additional ADSs before July 6, 2026, which, if fully exercised, could raise total proceeds to approximately $920 million, further strengthening the company's financial position for R&D and market expansion.
- Dilution Impact: The issuance of 6.4 million ADSs will result in an approximate 8% dilution of the company's share capital, increasing to 9.2% if the underwriters' option is fully exercised, which may affect existing shareholders' stakes and warrants investor attention.
See More
Abivax Upsizes Public Offering to $800M, Plans for Obefazimod Commercialization
- Offering Size Increased: Abivax SA has upsized its public offering from the initially planned $600 million to $800 million by pricing 6.4 million ADSs at $125 each, reflecting strong market demand for its products.
- Potential Financing Boost: The offering includes a 15% option for underwriters to purchase up to 960,000 additional ADSs, which could raise total gross proceeds to approximately $920 million if fully exercised, further strengthening the company's financial position.
- Clear Use of Proceeds: Abivax intends to use the proceeds to support the commercialization of obefazimod, fund clinical development, and for general corporate purposes, demonstrating the company's strong confidence in future product marketability.
- Expected Closing Date: The public offering is expected to close on July 6, 2026, marking an active capital market strategy that lays a solid foundation for the company's future growth.
See More
Latest Wall Street Rating Updates
- Abbott Labs Upgrade: Baird initiates coverage on Abbott Labs (ABT) with an outperform rating, projecting steady revenue and earnings growth of 6-8% over the next few years, bolstered by its leading position in the rapidly growing MedDevice market, enhancing the company's competitive edge.
- Murphy USA Upgrade: Jefferies upgrades Murphy USA (MUSA) from hold to buy, citing improving fuel margins that are expected to drive EBITDA outlook significantly higher by 20-25%, which will materially enhance the company's financial performance in the coming years.
- Abivax Upgrade: Jefferies raises Abivax (ABVX) to buy, noting strong data for its ulcerative colitis drug that alleviates key market concerns, which is likely to drive a rebound in the stock price.
- Talos Energy Upgrade: Roth upgrades Talos Energy (TALO) from neutral to buy, raising the price target by 6% to $17, based on its robust balance sheet and low production decline rates, indicating strong future growth potential.
See More
